【摘要】 目的评价3种三联疗法治疗幽门螺旋杆菌(HP)感染消化性溃疡的成本-效果,促进临床合理用药。方法选取HP阳性的消化性溃疡患者135例,分成3组。其中奥美拉唑组(OAC组)41例,泮托拉唑组(PAC组)44例,雷贝拉唑组(RAC组)50例。3组均加服克拉霉素与阿莫西林,比较用药14d后的疗效、不良反应和治疗成本,并进行药物经济学成本-效果分析。结果 3组治疗方案的成本分别为717.36元、777.84元、1060.92元;HP根除率分别为87.80%,90.91%,94.00%,3组无显著性差异;溃疡愈合率分别为78.05%,93.18%,96.00%,OAC组与PAC组比较有显著性差异。结论 PAC组是治疗消化性溃疡的最佳治疗方案。更多还原

【Abstract】 Objective To assess the cost-effectiveness of 3 kinds of triple therapy schemes in treating peptic ulcer with Helicobacter pylori(HP) infection for promoting clinical rational medication.Methods 135 patients with HP positive peptic ulcer were divided into three groups:the omeprazole group(OAC,n = 41),the pantoprazole group(PAC,n = 44) and rabeprazole(RAC,n = 50).The three groups were added with oral clarithromycin and amoxicillin.The curative effects,adverse reactions and treatment costs after 14 d treatment were compared among 3 groups by cost-effectiveness method.Results The costs of the OAC,PAC and RAC groups were 717.36 Yuan,777.84 Yuan and 1 060.92 Yuan respectively;the HP eradication rates were 87.80%,90.91% and 94.00%,without statistical difference;the ulcer healing rates were 78.05%,93.18% and 96.00% respectively,there was statistical difference between the OAC group and PAC group.Conclusion The PAC group is the optimal therapy scheme for treating HP positive peptic lcer更多还原